4//SEC Filing
Davis George Eric 4
Accession 0001048477-24-000112
CIK 0001048477other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 6:18 PM ET
Size
10.4 KB
Accession
0001048477-24-000112
Insider Transaction Report
Form 4
Davis George Eric
VP, General Counsel
Transactions
- Exercise/Conversion
Stock Option (Right to Buy Common Stock)
2024-05-28−40,850→ 0 totalExercise: $63.10From: 2014-12-04Exp: 2024-06-30→ Common Stock (40,850 underlying) - Exercise/Conversion
Common Stock
2024-05-28$63.10/sh+40,850$2,577,635→ 97,007 total - Sale
Common Stock
2024-05-28$74.45/sh−38,071$2,834,576→ 58,936 total - Sale
Common Stock
2024-05-28$75.29/sh−2,779$209,225→ 56,157 total
Footnotes (4)
- [F1]Trade made pursuant to a 10b5-1 plan executed on September 13, 2023.
- [F2]The price in column 4 is the weighted average price. The purchase price actually received ranged from $74.12 to $74.99. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- [F3]The price in column 4 is the weighted average price. The purchase price actually received ranged from $75.00 to $75.735. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
- [F4]Reflects the number of options outstanding after the transactions from this specific stock option grant.
Documents
Issuer
BIOMARIN PHARMACEUTICAL INC
CIK 0001048477
Entity typeother
Related Parties
1- filerCIK 0001380710
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 6:18 PM ET
- Size
- 10.4 KB